Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway

MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia

Scott A. Armstrong, Jane Staunton, Lewis B. Silverman et al. · Nature Genetics · 2001 · 1.7K citations

Hematological Malignancy, Chromatin, Distinct Gene Expression +12

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

Anne-Marie O'Farrell, Tinya J. Abrams, Helene A. Yuen et al. · Blood · 2003 · 856 citations · Full text

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

Mark J. Levis, Jeffrey Allebach, Kam-Fai Tse et al. · Blood · 2002 · 469 citations

Inhibition of FLT3 in MLL

Scott A. Armstrong, Andrew L. Kung, Meghann E. Mabon et al. · Cancer Cell · 2003 · 398 citations · Full text

Molecular Pharmacology, Molecular Regulation, Medicine +5

An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.

A O’Farrell, James M. Foran, Walter Fiedler et al. · PubMed · 2003 · 311 citations